Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 4/20 | 0.43 |
| ▸ | KRAS | P01116 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | TSPO | P30536 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7715925 | 0.84 | HTR6 (0.44) | ALDH1A1SMN1; SMN2KRASPTGDR2 | |
| SCHEMBL22798889 | 0.82 | ALDH1A1 (0.70) | LMNAALDH1A1SMN1; SMN2KRASMAPT | |
| SCHEMBL3406323 | 0.82 | TSPO (0.45) | LMNAALDH1A1SMN1; SMN2KRASTSPO | |
| SCHEMBL22122219 | 0.81 | KRAS (0.43) | ALDH1A1KRASPTGDR2 | |
| SCHEMBL15902156 | 0.80 | ALDH1A1 (0.67) | LMNAALDH1A1ATMMAPT | |
| SCHEMBL1614118 | 0.80 | KRAS (0.40) | LMNAALDH1A1SMN1; SMN2KRASMAPT | |
| SCHEMBL22128403 | 0.78 | L3MBTL1 (0.46) | LMNAALDH1A1SMN1; SMN2ELANEKRAS | |
| SCHEMBL22128307 | 0.78 | L3MBTL1 (0.46) | LMNAALDH1A1SMN1; SMN2ELANEKRAS | |
| SCHEMBL22128401 | 0.78 | L3MBTL1 (0.46) | LMNAALDH1A1SMN1; SMN2ELANEKRAS | |
| SCHEMBL22122394 | 0.78 | LMNA (0.43) | LMNAALDH1A1SMN1; SMN2ELANEKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047246-A1 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | LMNA 2969/4885ALDH1A1 1836/4885SMN1; SMN2 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.